Defining Disease Progression and Drug Durability in Type 2 Diabetes Mellitus
Authors:
Open Access
- 1 January 2019
- journal article
- Published by Touch Medical Media, Ltd. in touchREVIEWS in Endocrinology
- Vol. 15 (2) , 67-69
Abstract
This communication shares insights into the definition of disease progression and drug durability in type 2 diabetes. Disease progression may be defined as gradual worsening of beta-cell function, clinically observed as an increase in drug dosage, drug frequency or number of glucose lowering drugs needed to maintain HbA1c control; and/or a ≥0.5% rise in HbA1c, unexplained by acute, modifiable factors, while using the same drug regimen; and/or as the occurrence or worsening of cardiovascular or microvascular complications, in spite of standard care, over a pre-specified time period. Durability of a drug or a drug combination may be defined as its ability to postpone or delay progression of disease, in a safe and well tolerated manner. Thus, all drugs that are able to prevent disease progression (i.e., postpone loss of glycaemic control, need for intensification of therapy or onset or worsening of complications) may be termed 'durable'.Keywords
Funding Information
- This article is published under the Creative Commons Attribution Non-commercial License.
This publication has 28 references indexed in Scilit:
- Regulatory Scientific Advice on Non-Inferiority Drug TrialsPLOS ONE, 2013
- The dirty dozen of diabetesIndian Journal of Endocrinology and Metabolism, 2013
- A review of the efficacy and safety of oral antidiabetic drugsExpert Opinion on Drug Safety, 2012
- Defining and Characterizing the Progression of Type 2 DiabetesDiabetes Care, 2009
- From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes MellitusDiabetes, 2009
- Clinical Predictors of Disease Progression and Medication Initiation in Untreated Patients With Type 2 Diabetes and A1C Less Than 7%Diabetes Care, 2008
- Progression From Newly Acquired Impaired Fasting Glusose to Type 2 DiabetesDiabetes Care, 2007
- Glycemic Durability of Rosiglitazone, Metformin, or Glyburide MonotherapyNew England Journal of Medicine, 2006
- Coefficient of failure: a methodology for examining longitudinal β‐cell function in Type 2 diabetesDiabetic Medicine, 2002
- Understanding the nature of renal disease progressionKidney International, 1997